About
38.87USD-0.37 -0.94%
Closed • Updated at 21:18 GMT+00:00Market Cap$5.95B
P/E Ratio13.55
Volume1.36M
Beta0.71
RSI53.26
Gross Margin83.05%
Tg Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 6 2026
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
Apr 30 2026
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Apr 22 2026
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
Apr 15 2026
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Mar 19 2026
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Community Chat
Ask AI
Try asking
Translate